Table 1.

Effects of canagliflozin on eGFR slope by screening eGFR

N Canagliflozin/PlaceboCanagliflozinPlaceboDifference (95% CI)P ValueP Interaction
eGFR change from baseline to week 3 (ml/min per 1.73 m2)
 All (unstructured)2179/2178−3.72 (0.25)−0.55 (0.25)−3.17 (–3.87 to –2.47)<0.001
 eGFR 30 to <45645/648−2.45 (0.25)−0.41 (0.25)−2.03 (–2.73 to –1.34)<0.0010.02
 eGFR 45 to <60635/635−4.08 (0.32)−0.64 (0.31)−3.44 (–4.32 to –2.57)<0.001
 eGFR 60 to <90899/895−3.66 (0.32)−0.39 (0.33)−3.27 (–4.17 to –2.37)<0.001
Annual eGFR change from week 3 to last available measurement (ml/min per 1.73 m2 per yr)
 All (unstructured)2081/2095−1.85 (0.13)−4.59 (0.14)2.74 (2.37 to 3.11)<0.001
 eGFR 30 to <45611/622−1.72 (0.20)−4.33 (0.20)2.61 (2.06 to 3.16)<0.0010.65
 eGFR 45 to <60605/613−1.62 (0.23)−4.58 (0.24)2.97 (2.32 to 3.61)<0.001
 eGFR 60 to <90865/860−2.32 (0.23)−4.92 (0.23)2.60 (1.97 to 3.23)<0.001
Annual eGFR change from baseline to week 130 (ml/min per 1.73 m2 per yr)
 All (unstructured)2179/2178−3.19 (0.15)−4.71 (0.15)1.52 (1.11 to 1.93)<0.001
 eGFR 30 to <45645/648−2.56 (0.21)−4.35 (0.21)1.79 (1.20 to 2.38)<0.0010.71
 eGFR 45 to <60635/635−3.11 (0.25)−4.76 (0.25)1.65 (0.96 to 2.34)<0.001
 eGFR 60 to <90899/895−3.61 (0.24)−5.03 (0.24)1.42 (0.75 to 2.09)<0.001
  • Data in the columns of canagliflozin and placebo are mean (SEM). The effects of canagliflozin on the mean on-treatment eGFR slope were analyzed using a two-slope linear spline model for eGFR, with a knot at week 3 to account for separate acute (baseline to week 3) and chronic (week 3 to end of treatment) slopes. The full model also included random intercepts and acute and chronic slopes. When the full model failed to converge, a simplified model with a random intercept and a single random slope was used. The mean total slope was computed as a weighted combination of the acute and chronic slopes to reflect the mean rate of eGFR change to week 130.